NK vs. NVAX, VALN, ALLO, MESO, FATE, PROK, PRME, EXAI, ALEC, and HLVX
Should you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Novavax (NVAX), Valneva (VALN), Allogene Therapeutics (ALLO), Mesoblast (MESO), Fate Therapeutics (FATE), ProKidney (PROK), Prime Medicine (PRME), Exscientia (EXAI), Alector (ALEC), and HilleVax (HLVX). These companies are all part of the "medical" sector.
Novavax (NASDAQ:NVAX) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
Novavax received 568 more outperform votes than NantKwest when rated by MarketBeat users. Likewise, 74.29% of users gave Novavax an outperform vote while only 53.85% of users gave NantKwest an outperform vote.
In the previous week, Novavax had 3 more articles in the media than NantKwest. MarketBeat recorded 3 mentions for Novavax and 0 mentions for NantKwest. NantKwest's average media sentiment score of 0.44 beat Novavax's score of 0.00 indicating that Novavax is being referred to more favorably in the media.
53.0% of Novavax shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 0.9% of Novavax shares are owned by insiders. Comparatively, 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
NantKwest has lower revenue, but higher earnings than Novavax. NantKwest is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Novavax has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500.
Novavax currently has a consensus price target of $17.00, suggesting a potential upside of 305.73%. Given NantKwest's higher possible upside, equities research analysts clearly believe Novavax is more favorable than NantKwest.
Novavax has a net margin of -55.41% compared to Novavax's net margin of -76,658.58%. NantKwest's return on equity of 0.00% beat Novavax's return on equity.
Summary
Novavax beats NantKwest on 12 of the 17 factors compared between the two stocks.
Get NantKwest News Delivered to You Automatically
Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NantKwest Competitors List
Related Companies and Tools
